Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2014 Feb;95(2):141-6.
doi: 10.1038/clpt.2013.203. Epub 2013 Oct 4.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens

A J Muir  1 , L Gong  2 , S G Johnson  3 , M T M Lee  4 , M S Williams  5 , T E Klein  2 , K E Caudle  6 , D R Nelson  7 ; Clinical Pharmacogenetics Implementation Consortium (CPIC)
Affiliations
Practice Guideline

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens

A J Muir et al. Clin Pharmacol Ther. 2014 Feb.

Abstract

Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-α- and RBV-containing regimens based on IFNL3 genotype.

PubMed Disclaimer

References

    1. Kronenberger B., Zeuzem S. Current and future treatment options for HCV. Ann. Hepatol. 2009;8:103–112. - PubMed
    1. van der Meer A.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–2593. - PubMed
    1. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. American Association for the Study of Liver Diseases Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374. - PMC - PubMed
    1. Conjeevaram H.S., et al. Virahep-C Study Group Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470–477. - PubMed
    1. Muir A.J., Bornstein J.D., Killenberg P.G. Atlantic Coast Hepatitis Treatment Group Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med. 2004;350:2265–2271. - PubMed

Publication types

MeSH terms

LinkOut - more resources